Annovis Provides Corporate Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results
Provided By GlobeNewswire
Last update: Mar 21, 2025
MALVERN, Pa., March 21, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis" or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today provided corporate updates and fourth quarter/full year 2024 financial results.
Read more at globenewswire.com
